How to Reverse an Opioid Overdose with Naloxone (Narcan)

This comprehensive protocol covers the complete emergency response for suspected opioid overdose: (1) Initial assessment - check pulse and breathing, call for help and AED, provide ventilations if pulse present but no breathing; (2) Naloxone administration - 2mg dose via nasal atomizer (1cc per nostril), atomized into fine mist; (3) Monitoring - Naloxone takes 3-5 minutes for effect, duration shorter than opioids, requires 2-hour observation; (4) CPR protocol - lay-rescuers start CPR, providers check pulse for rescue breathing vs full CPR; (5) Response assessment - if no change in 3-5 minutes, administer additional Naloxone; (6) Alternative diagnosis - if second dose fails, opioids may be absent or unusually strong.

This segment provides a comprehensive demonstration of CPR (Cardiopulmonary Resuscitation) for an overdose victim. The emergency operator guides the caller through the complete procedure: opening the airway by tilting the head back, checking for breathing, performing rescue breathing (two deep breaths with lips sealed over the mouth), and executing chest compressions (15 compressions in the center of the chest between the nipples). The operator emphasizes maintaining a steady rhythm and continuing the cycle of 2 breaths and 15 compressions until emergency services arrive. This demonstrates the critical importance of immediate bystander intervention in overdose situations.

In an opioid overdose situation, perform rescue breathing by opening the airway, pinching the nose, and giving one-second breaths until chest rises; then perform 30 chest compressions (pushing 2 inches deep at 100-120 per minute) after every two breaths, continuing until the person breathes normally, regains consciousness, or professional help arrives.

To administer rescue breathing during an overdose, first check if the person is breathing by placing them on their back, tilting their head back, lifting their chin, and listening for breath sounds while watching chest movement for five seconds; if not breathing, check for a pulse, call 9-1-1, clear the airway, pinch the nose, lift the chin, form a tight seal, and deliver two initial breaths followed by one breath every five seconds for two minutes, ensuring the chest rises but not the stomach.

Effective overdose response follows a systematic protocol: 1) Verbally check the person and call 9-1-1 immediately, 2) Administer naloxone (4mg) into one nostril, 3) Begin rescue breathing with a barrier device, giving two initial breaths then one every five seconds, 4) If no response after 1-2 minutes, administer a second dose in the opposite nostril. For rigid victims, do not move them to prevent spinal injury. Place them in recovery position to keep airways clear and prevent aspiration. If sitting rigid, fold them forward by armpits. If against a wall, tilt head to side with skull on wall. The three key takeaways are: Naloxone, Call 9-1-1, and Air (rescue breathing).

Naloxone (Narcan) is a high-affinity mu receptor antagonist that reverses opioid overdose by binding more tightly to opioid receptors than the opioid itself, displacing it and restoring breathing. However, naloxone has a very short half-life (30 minutes to 1 hour) compared to most opioids (8+ hours, especially fentanyl), meaning it wears off before the opioid is eliminated. This necessitates continuous monitoring and emergency medical care. Despite this limitation, naloxone has an excellent safety profile with no dependence or tolerance development. It has no clinical effects in the absence of opioids—if administered to someone not experiencing an opioid overdose, it will not cause harm. The FDA has recommended naloxone for over-the-counter availability, reflecting its safety profile. Naloxone can precipitate opioid withdrawal symptoms, causing nausea and discomfort, which is why explaining what is happening to the person receiving it is important.

Naloxone reverses opioid overdose through opioid receptor antagonism. IV/IM/intranasal routes available with 20-90 minute duration. Dosing: start 0.04 mg IV, repeat every 2 minutes up to 15 mg total. Empiric dosing guided by clinical response. No evidence supports concerns about precipitating seizures/withdrawal in chronic users. Post-naloxone observation required 4-6 hours due to shorter naloxone half-life. Avoid bicarbonate as it precipitates overdose and prolongs drug effects.

Naloxone is a competitive reversible opioid antagonist used for overdose reversal. Therapeutic indications include CNS and respiratory depression reversal in adults and neonates exposed to opioids in utero. Initial dosing follows titration: 0.4 mg IV for suspected dependence (max 15 mg) or 0.04 mg/kg for unknown dependence, titrated to 0.4 mg/kg with 2-3 minute reevaluation. If no response, infusion begins at two-thirds of the stabilizing dose, administered continuously until respiratory pattern stabilizes. Naloxone's short half-life requires ongoing monitoring, as patients may deteriorate as the drug wears off, particularly with long-acting opioids like methadone (4 times longer than naloxone). Care must be taken as naloxone can precipitate non-cardiogenic pulmonary edema.

Opioid overdose causes respiratory depression due to excessive respiratory center inhibition. Signs include shallow respirations, cyanosis, and unconsciousness. Naloxone is the reversal agent, administered IV (4mg initial dose). However, naloxone has critical limitations: its effects last only ~1 hour while morphine's half-life is 4-5 hours, requiring repeated dosing. Most critically, naloxone is contraindicated in chronic opioid users as it precipitates severe withdrawal that may drive addicts to seek more drugs or commit suicide.

After naloxone administration, several critical considerations apply. Naloxone wears off in 30-90 minutes (longer with fentanyl or high opioid doses), and the opioids still in the person's body can cause them to overdose again as soon as naloxone wears off. The person should be monitored until emergency medical services arrives and informed that naloxone causes withdrawal symptoms and may cause re-overdose. If EMS is not coming, the person should visit a doctor as soon as possible because they may have vomited and could choke, may have fluid in their lungs (pneumonia), or may have sustained head injuries (concussion) during the overdose. Critical warning signs include: do not leave the person alone, do not put them in a bath (drowning risk), do not induce vomiting (choking risk), do not give them anything to drink, do not put ice down their pants (slows breathing), and do not inject anything other than naloxone.

The Good Samaritan law in Iowa is a harm reduction policy that encourages people to call 9-1-1 even in cases of drug overdose, even if they have substances or paraphernalia on their person. This law helps people feel more comfortable calling for help and protects people who are in a position to help someone experiencing an overdose, such as by using Narcan. While not perfect, it represents an important policy approach to harm reduction.

The United States continues to face a severe drug overdose crisis, with nearly 107,000 deaths annually, largely driven by opioids and stimulants. While incremental reforms have expanded naloxone access (now available in 39 states for lay distribution, 16 states allowing possession without prescription, and some formulations now OTC), drug paraphernalia laws and overdose Good Samaritan laws remain heavily restrictive. Paraphernalia laws, originally designed by the DEA in 1979 to broadly criminalize drug consumption equipment, create confusion and barriers to harm reduction despite public health evidence supporting decriminalization. Similarly, Good Samaritan laws in 48 states provide limited protection primarily from minor drug offenses, failing to address broader systemic barriers like probation violations, CPS involvement, or housing instability. True reform requires shifting from immunity exceptions to default protection models, as demonstrated by Maine's 2022 legislation granting immunity to everyone at overdose scenes. The fundamental principle is that every policy produces the results it is designed to produce—if the goal is saving lives, then immunity should be the default rather than the exception.

Harm reduction has strong evidence-based public health applications including overdose prevention with naloxone, syringe and needle programs, safer consumption sites, and opiate substitution treatments like methadone and buprenorphine. These interventions save lives and help people stay safe. The Good Samaritan Law protects people who call for help during drug-related emergencies from arrest and prosecution. In some European countries and Canada, heroin maintenance treatment has been found effective for people unresponsive to other medications. These public health interventions form the foundation for therapeutic work, creating points of contact where people can engage with healthcare and helping professions.

Effective policy interventions include Good Samaritan laws (protecting those who call 911 during overdoses) and Prescription Monitoring Programs (PMPs). However, Good Samaritan laws require education in communities of color because many fear police. Organizations should establish relationships with local public health professionals, train staff on naloxone administration, and develop policies ensuring ongoing training. Clients and family members should be educated about naloxone because users cannot administer it to themselves.

Harm reduction is a public health approach acknowledging humans engage in risky behaviors daily, whether legal (seatbelts, condoms) or illegal (drug use). It provides strategies to reduce harm without requiring abstinence. The philosophy recognizes drug use has existed for over 8,000 years and won't disappear, so criminalization fails. Many U.S. drug laws were rooted in racism rather than science: cocaine prohibition targeted African-Americans, opium criminalization targeted Chinese immigrants, and marijuana prohibition targeted Mexican workers. This historical context explains why substance use disproportionately impacts marginalized communities today. Syringe service programs originated in the Netherlands in the 1970s-1980s responding to hepatitis outbreaks, and in the U.S. in the early 1980s responding to HIV. Research shows these programs reduce HIV and hepatitis C risk by approximately 50% among people who inject drugs. CDC research confirms that syringe access users are five times more likely to enter treatment, demonstrating that respectful, non-judgmental engagement builds trust and facilitates recovery pathways. Language significantly impacts perception: person-first language ('a person who uses drugs' vs. 'addict') recognizes identity beyond substance use. The opposite of addiction is connection—not sobriety. Trauma-informed care asks 'what's happened to you?' rather than 'what's wrong with you?' Legal protections enable harm reduction: certified syringe exchange participants receive identification cards exempting them from paraphernalia charges. Good Samaritan laws protect anyone administering naloxone from criminal liability during overdose events, regardless of other substances involved.